The ``priority review vouchers'' for neglected pharmaceutical innovation and their impact on pharmaceutical patents

Article type: Research Article

Authors: Sanchez, Alfonso Calles

Affiliations: Center for European Studies, Duke University, Durham, NC, USA

Note: [] Corresponding author: Alfonso Calles Sanchez, Av. Fco. Fdez. Ordonez 27, 4C, Getafe, Madrid, Spain. Tel.: +34 699 56 93 08, +32 497 62 48 54, +374 99 99 61 02; E-mail: [email protected]

Abstract: The priority review voucher scheme is a strong market-driven incentive which complements existing incentives for pharmaceutical research on neglected diseases. Contrary to other market based incentives, the PRV reconciles the need for innovation with generic manufacturers' business plans – since the PRV scheme does not delay generic competition while extending effective patent life.

Keywords: Priority review voucher, neglected diseases, patent, pharmaceutical, drug, SPC, patent extention, FDA, EMA

DOI: 10.3233/PPL-140374

Journal: Pharmaceuticals, Policy and Law, vol. 16, no. 1-2, pp. 167-172, 2014